AstraZeneca to Make $2 Billion Manufacturing Investment in Maryland

Dow Jones

2025/11/22

By Elias Schisgall

AstraZeneca is planning to make a $2 billion investment to expand its manufacturing footprint in Maryland.

The pharmaceutical company said Friday the investment will be for the construction of a new laboratory in Gaithersburg, Md., and to expand its existing facility in Frederick. The investment will create 1,900 construction jobs and 300 new, high-skilled positions across both projects.

The new commitment is part of AstraZeneca's pledge in July to invest $50 billion in U.S. operations. The company has already put capital toward new facilities in Rockville and in Virginia, as well as expanding an existing facility in Coppell, Texas.

Expansion of the Frederick facility will double the company's capacity to manufacture biologics and allow for the production of medicines across its rare disease portfolio.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

November 21, 2025 14:42 ET (19:42 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2585123508"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585123508\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585123508?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-22 03:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585123508","market":"hk","top_or_hot":-1,"title":"AstraZeneca to Make $2 Billion Manufacturing Investment in Maryland","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AstraZeneca is planning to make a $2 billion investment to expand its manufacturing footprint in Maryland. \n</p>\n<p>\n  The pharmaceutical company said Friday the investment will be for the construction of a new laboratory in Gaithersburg, Md., and to expand its existing facility in Frederick. The investment will create 1,900 construction jobs and 300 new, high-skilled positions across both projects. \n</p>\n<p>\n  The new commitment is part of AstraZeneca's pledge in July to invest $50 billion in U.S. operations. The company has already put capital toward new facilities in Rockville and in Virginia, as well as expanding an existing facility in Coppell, Texas. \n</p>\n<p>\n  Expansion of the Frederick facility will double the company's capacity to manufacture biologics and allow for the production of medicines across its rare disease portfolio. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2025 14:42 ET (19:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to Make $2 Billion Manufacturing Investment in Maryland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to Make $2 Billion Manufacturing Investment in Maryland\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-22 03:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AstraZeneca is planning to make a $2 billion investment to expand its manufacturing footprint in Maryland. \n</p>\n<p>\n  The pharmaceutical company said Friday the investment will be for the construction of a new laboratory in Gaithersburg, Md., and to expand its existing facility in Frederick. The investment will create 1,900 construction jobs and 300 new, high-skilled positions across both projects. \n</p>\n<p>\n  The new commitment is part of AstraZeneca's pledge in July to invest $50 billion in U.S. operations. The company has already put capital toward new facilities in Rockville and in Virginia, as well as expanding an existing facility in Coppell, Texas. \n</p>\n<p>\n  Expansion of the Frederick facility will double the company's capacity to manufacture biologics and allow for the production of medicines across its rare disease portfolio. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2025 14:42 ET (19:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2585123508","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585123508","pubTimestamp":1763754120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AstraZeneca is planning to make a $2 billion investment to expand its manufacturing footprint in Maryland.The pharmaceutical company said Friday the investment will be for the construction of a new laboratory in Gaithersburg, Md., and to expand its existing facility in Frederick. The investment will create 1,900 construction jobs and 300 new, high-skilled positions across both projects.The new commitment is part of AstraZeneca's pledge in July to invest $50 billion in U.S. operations. The company has already put capital toward new facilities in Rockville and in Virginia, as well as expanding an existing facility in Coppell, Texas.Expansion of the Frederick facility will double the company's capacity to manufacture biologics and allow for the production of medicines across its rare disease portfolio.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"阿斯利康将在马里兰州投资20亿美元制造业","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  AstraZeneca is planning to make a $2 billion investment to expand its manufacturing footprint in Maryland. \n\n\n  The pharmaceutical company said Friday the investment will be for the construction of a new laboratory in Gaithersburg, Md., and to expand its existing facility in Frederick. The investment will create 1,900 construction jobs and 300 new, high-skilled positions across both projects. \n\n\n  The new commitment is part of AstraZeneca's pledge in July to invest $50 billion in U.S. operations. The company has already put capital toward new facilities in Rockville and in Virginia, as well as expanding an existing facility in Coppell, Texas. \n\n\n  Expansion of the Frederick facility will double the company's capacity to manufacture biologics and allow for the production of medicines across its rare disease portfolio. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 14:42 ET (19:42 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}